Skip to main content
Premium Trial:

Request an Annual Quote

RXi, Generex See Positive Early Data from Vaccine Collaboration


RXi Pharmaceuticals said this week that it has obtained "positive early research data" in its collaboration with Generex Biotechnology subsidiary Antigene Express to use RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

According to RXi, the data show that its self-delivering RNAi molecules can silence target genes up to 80 percent in hemopoietic cells.

"The ability to knock down expression of certain genes in isolated hemopoietic-derived cancer cells has the potential to convert them into specific immune-stimulants and opens the possibility for development of a new class of anticancer therapeutic vaccines," the company said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.